AstraZeneca: two trials show long-term efficacy and tolerability of Calquence (acalabrutinib) in chronic lymphocytic leukaemia

ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more than four years In pivotal ASCEND trial, 82% of patients with relapsed or refractory disease treated with Calquence remained progression … Read the full press release →